Author: Ravi Shankar

Transaction in Own Shares

September 28, 2026

• • • • • • • • • • • • • • • •

Shell plc (the ‘Company’) announces that on 28 September 2026 it purchased the following number of Shares for cancellation.

Aggregated information on Shares purchased according to trading venue:

Date of Purchase	Number of Shares purchased	Highest price paid	Lowest price paid	Volume weighted average price paid per share	Venue	Currency
28/09/2026	1,100,000	£ 36.8150	£ 36.4400	£ 36.6222	LSE	GBP
28/09/2026	300,000	£ 36.8150	£ 36.4400	£ 36.6212	Chi-X (CXE)	GBP
28/09/2026	–	–	–	–	BATS (BXE)	GBP
28/09/2026	550,000	€ 42.9950	€ 42.5700	€ 42.8005	XAMS	EUR
28/09/2026	–	–	–	–	CBOE DXE	EUR
28/09/2026	–	–	–	–	TQEX	EUR

These share purchases form part of the on- and off-market limbs of the Company’s existing share buy-back programme previously announced on 30 July 2026. 

In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 30 July 2026 up to and including 23 October 2026.

The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market. The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein. The programme will be conducted in accordance with Chapter 9 of the UK Listing Rules and Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (“EU MAR”) and EU MAR as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020)  through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time (“UK MAR”) and the Commission Delegated Regulation (EU) 2016/1052 (the “EU MAR Delegated Regulation”) and the EU MAR Delegated Regulation as “onshored” into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020), and as amended, supplemented, restated, novated, substituted or replaced by the Financial Services Act, 2021 and relevant statutory instruments (including, The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310)), from time to time.

In accordance with EU MAR and UK MAR, a breakdown of the individual trades made by Goldman Sachs International on behalf of the Company as a part of the buy-back programme is detailed below.

Enquiries:

Media International: +44 (0) 207 934 5550; U.S. and Canada: https://www.shell.us/about-us/news-and-insights/media/submit-an-inquiry.html

Attachment

• 20260928_Shell RNS – full version

– KO-7246 regenerated functional β–cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –

– KO-7246 has potential to complement existing diabetes therapies with a novel mechanism of action, evidenced by post-treatment durability and combination benefit with semaglutide –

– Findings highlight a potentially disease-modifying approach designed to restore the body’s own endogenous insulin-producing capacity –

– Caspian is building a leadership position in menin-directed therapies for diabetes and other cardiometabolic diseases –

– Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for diabetes. KO-7246 regenerated functional β-cell mass, demonstrated durable glycemic control, and increased endogenous insulin production in preclinical models of Type 1 and Type 2 diabetes. In human islets, KO-7246 selectively increased β-cell proliferation and improved glucose-responsive insulin secretion. Together, the findings establish a differentiated preclinical profile including validated activity as a menin inhibitor, durable disease-relevant activity, and confirmed translation to a human-islet setting.

The data were generated by Kura Oncology prior to the launch of Caspian in September 2026. Francis Burrows, Ph.D., Chief Scientific Officer of Kura Oncology, presented the findings today at the 62^nd European Association for the Study of Diabetes Annual Meeting (EASD) in Milan, Italy.

Menin acts as a molecular brake on pancreatic β-cell proliferation. With its menin inhibitor platform, Caspian is pursuing a potentially disease-modifying approach designed to increase functional β-cell mass and restore the body’s insulin-producing capacity.

“Menin is a compelling target in diabetes because multiple lines of evidence, from human physiology and genetics to pharmacologic studies, point to its role in regulating β-cell mass,” said Dr. Burrows. “KO-7246 gives us a potent, selective way to test whether menin inhibition can harness this biology to restore endogenous insulin-producing capacity in both Type 1 and Type 2 diabetes. Its potency and selectivity as a menin inhibitor, as well as its activity in a range of diabetes preclinical models, distinguish KO-7246 from earlier approaches and support its potential to become a best-in-class menin inhibitor for diabetes.”

In a rat model of Type 1 diabetes, KO-7246 normalized fasting blood glucose in a majority of animals and increased stimulated C-peptide, a marker of endogenous insulin production. Among responder animals, pancreatic islets regenerated to 40-90% of levels seen in healthy controls by Day 56. Importantly, normalized glucose levels and increased C-peptide were maintained for at least one month after treatment was stopped, while residual cell proliferation was negligible. Together, these findings suggest that KO-7246 rebuilt functional β-cell capacity and that the benefit persisted after dosing ended. The dependence of response on residual β-cell capacity at the baseline was also consistent with the proposed regenerative mechanism.

In a mouse model of Type 2 diabetes, KO-7246 significantly reduced fasting blood glucose, increased insulin and C-peptide levels, and produced a 3.4-fold increase in β-cell mass. KO-7246 also demonstrated enhanced activity in combination with semaglutide, highlighting its potential to complement existing GLP-1 therapies. The increase in insulin was not associated with hypoglycemia. These findings suggest that KO-7246 could provide a differentiated therapeutic benefit as either a monotherapy or a complement to widely used glucose-lowering treatments.

In human pancreatic islet models, KO-7246 increased β-cell proliferation and the proportion of β-cells without stimulating growth of other islet cells, and improved insulin release in response to glucose. These findings provide additional evidence that the regenerative effects observed in animal models extend to human β-cell systems. The selective effect on β-cells further differentiates KO-7246 from broader proliferative approaches that could stimulate non-β-cell growth.

The presentation included data highlighting KO-7246’s differentiated pharmacology compared to other targeted therapies in clinical development for diabetes. KO-7246 demonstrated potent menin inhibition in biochemical and cellular assays, while BMF-219 (icovamenib) showed no discernable activity against menin in the biochemical assay but instead inhibited several kinases, including CDK9. In vivo evidence of bona fide menin pharmacology was demonstrated with KO-7246 in a menin-dependent leukemia model, while BMF-219 showed no efficacy even at an 8-fold higher daily dose. In the Type 1 diabetes model, where KO-7246 restored glycemic control and increased β-cell mass, BMF-219 did not produce either of these effects. Taken together, these comparative results support KO-7246’s profile as a bona fide and highly selective menin inhibitor with potential as a differentiated therapy for diabetes.

“We believe KO-7246 has one of the most comprehensive preclinical profiles reported for a menin inhibitor being developed for diabetes. It combines bona fide menin pharmacology with durable β-cell regeneration, activity in both Type 1 and Type 2 diabetes models, and potent and selective effects on β cells in human islets,” said Robert Spencer, Ph.D., President and Chief Operating Officer of Caspian Therapeutics. “Caspian was formed to translate this biology into potentially disease-modifying medicines. We believe these data provide a strong foundation for KO-7246 to become a best-in-class menin inhibitor and for Caspian to lead the development of menin-directed therapies for diabetes and other cardiometabolic diseases. We are advancing KO-7246 through IND-enabling development toward initial clinical evaluation.”

Virtual Investor Event

Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. ET. The live webcast and replay will be available on www.kuraoncology.com under the Investors tab in the Events and Presentations section.

About Caspian Therapeutics

Caspian Therapeutics is pioneering menin-directed therapies in diabetes and other cardiometabolic diseases. Built on more than a decade of menin-inhibitor research at Kura Oncology, Caspian combines deep expertise in menin biology and medicinal chemistry with a development strategy focused on the requirements of diabetes and other cardiometabolic diseases.

Caspian’s lead compound, KO-7246, is a next-generation, highly selective and orally bioavailable menin inhibitor intended for metabolic applications and is currently in IND-enabling development. Caspian plans to evaluate KO-7246 in a Phase 1 program designed to assess its potential to restore functional β-cell capacity and endogenous insulin production in patients with diabetes. Caspian also plans to advance a second development candidate for additional cardiometabolic indications. To learn more, visit www.caspiantherapeutics.com.

Kura Oncology Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the potential for KO-7246 to be a best-in-class menin inhibitor for diabetes, represent a disease-modifying approach to the disease, and restore the body’s endogenous insulin-producing capacity; the strength of the preclinical findings related to KO-7246; the therapeutic potential of, opportunity for and differentiated approach for KO-7246; the potential for KO-7246 to provide a differentiated therapeutic benefit as either a monotherapy or a complement to widely used glucose-lowering treatments such as GLP-1 therapies; the potential for the regenerative effects of KO-7246 observed in animal models to extend to human β-cell systems; the potential for Caspian to lead the development of menin-directed therapies for diabetes and other cardiometabolic diseases; and Caspian’s plans to evaluate KO-7246 in a Phase 1 program designed to assess its potential to restore functional β-cell capacity and endogenous insulin production in patients with diabetes and to advance a second development candidate for additional cardiometabolic indications. Factors that may cause actual results to differ materially include risks associated with the conduct of preclinical studies and clinical trials; the risk of the FDA not permitting Kura’s or Caspian’s planned trials to proceed; the risk that Kura’s or Caspian’s product candidates may not receive regulatory approval; the potential for Kura’s or Caspian’s product candidates to have unexpected adverse side effects; the risk that Kura or Caspian may not be able to obtain additional financing; the risks associated with reliance on outside financing to meet capital requirements; the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials; risks associated with reliance on third parties to successfully conduct clinical trials; and other risks associated with the process of discovering, developing and commercializing drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Caspian Therapeutics
Robert Spencer, Ph.D.
rob@caspiantx.com

Kura Oncology
Greg Mann
858-987-4046
gmann@kuraoncology.com

MEDFORD, Ore., Sept. 29, 2026 (GLOBE NEWSWIRE) — Lithia & Driveway (NYSE: LAD) today announced its third quarter 2026 results will be released before the market opens on Wednesday, October 21, 2026. A conference call to discuss the earnings results is scheduled for the same day at 10:00 a.m. Eastern Time.

How to Participate

The conference call may be accessed by telephone at (877) 407-8029. To listen live on our website, or for replay, visit investors.lithiadriveway.com and click on quarterly earnings.

About Lithia & Driveway (LAD)
Lithia & Driveway (NYSE: LAD) is the largest global automotive retailer making Auto Done Easy by providing simple, transparent, and convenient experiences throughout the ownership lifecycle. LAD helps customers take care of any vehicle need through a comprehensive network of physical locations, e-commerce platforms, captive finance solutions, fleet management offerings, and other synergistic adjacencies. Celebrating 80 years in business in 2026, LAD consistently delivers profitable growth in a massive and unconsolidated industry. Its highly diversified and competitively differentiated design provides LAD with the flexibility and scale to pursue its vision to modernize personal transportation solutions wherever, whenever and however consumers desire.

The 80th Celebration
https://www.lithiadriveway.com/80-years

Connect with Us!
All Cars: https://www.lithia.com
Driveway.com (Buy, sell, trade, or finance entirely online): https://www.driveway.com
GreenCars (All things sustainable vehicles): https://www.greencars.com
DFC (Auto Financing): https://www.drivewayfinancecorp.com
Investor Relations: https://investors.lithiadriveway.com/
Careers: https://www.lithiacareers.com
Lithia & Driveway on Instagram
https://www.instagram.com/lithiamotors/?hl=en
https://www.instagram.com/driveway_hq/
Lithia & Driveway on Facebook
https://www.facebook.com/lithiaanddriveway/
https://www.facebook.com/DrivewayHQ
Lithia & Driveway on X
https://x.com/lithiadriveway
https://x.com/DrivewayHQ
https://x.com/GreenCarsHQ
Lithia & Driveway on LinkedIn
https://www.linkedin.com/company/lithia-motors/
Lithia & Driveway on YouTube
https://www.youtube.com/@LithiaDriveway

CONTACT: Media Contact
lithia@skyya.com 

Strategic integration brings OpenRTB standards to onsite retail inventory across the US and Europe, enabling brands to activate high-intent placements alongside omnichannel campaigns

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, and Koddi, a leading commerce media platform, today announced a global partnership delivering an open, universal OpenRTB standard for onsite retail media inventory. Building on Teads’ position as an early innovator in bringing real-time bidding (RTB) capabilities to native retail listings, this strategic collaboration directly tackles the top challenges facing advertisers today: according to IAB Europe’s Attitudes to Retail Media report, the fragmentation of retail media networks (51%) and a lack of standardization (53%) remain the primary barriers for buy-side stakeholders.

The integration enables advertisers to unify onsite retail media with their broader omnichannel strategy, seamlessly activating Sponsored Product Ads (SPAs) and high-intent Display placements in Teads Ad Manager across Koddi-powered networks in the US and Europe, including platforms such as Gopuff UK, Hopper, and Wolt Ads.

“At Wolt Ads, we’re focused on giving brands more ways to reach highly engaged, high-intent shoppers across our platform,” said Catalina Salazar, Global Head of Advertising at Wolt. “Opening our marketplace to differentiated demand partners like Teads via Koddi Ads lets us bring in incremental demand via the buying platform of the advertiser’s choice while maintaining full control over how our inventory is monetized.”

Retailers using Koddi Ads are adopting open programmatic to maximize inventory yield and meet demand in their preferred DSP. Supported by sales teams in over 55 countries, Teads supports Koddi Ads retailer partners, like Wolt Ads, with scaled and differentiated advertiser demand.

“Advertisers can activate retail media as part of their broader omnichannel strategy in Teads Ad Manager, reducing complexity while maximizing their campaign’s performance,” said Justin Sparks, GM of Retail & Commerce Media at Teads. “By embracing OpenRTB as a standardization framework, retailers unlock access to significantly more demand by opening up to omnichannel DSPs like ours. We believe this partnership represents the future of retail media: open, standardized, and integrated into the broader advertising ecosystem, connecting shopper and national brand dollars to the same pipes globally.”

Koddi’s commerce media platform enables retailers to open their valuable onsite inventory programmatically while maintaining complete control over inventory, pricing, and quality standards. Through this partnership, enterprise networks using Koddi’s platform can now access Teads’ global advertiser base seamlessly without managing custom, proprietary integrations.

“Our integration with Teads represents a significant milestone in making retail media truly programmatic on a global scale,” said Nicholas Ward, President at Koddi. “By connecting premium demand from Teads’ global advertiser ecosystem with retailers’ high-intent onsite inventory across markets, we’re empowering brands to scale retail media activation efficiently while giving retailers access to meaningful incremental demand.”

This partnership establishes a foundation for expanded ad format support and additional retail partnerships across markets in the future.

About Teads

Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full-funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

About Koddi

Koddi is the leading retail and commerce media technology for enterprises. Leveraging AI and first-party data, Koddi builds retail and commerce media networks for the biggest companies in the world, including Booking.com, Kroger, Fanatics, and Cars.com. With more than a decade of experience and powering billions of media spend, the company is leading the fast-growing rise of commerce and retail media. Koddi supplies technologies that empower retailers, marketplaces, online travel agencies and more to realize the $100 billion commerce media opportunity. For more information, please visit koddi.com.

About Wolt
Wolt is a Helsinki-based technology company with a mission to bring joy, simplicity, and earnings to the neighborhoods of the world. Wolt develops a local commerce platform that connects people looking to order food, groceries, and other goods with people interested in selling and delivering them. Wolt was founded in 2014 and joined forces with DoorDash in 2022. Altogether, DoorDash operates in more than 40 countries today. You can read more on the Wolt website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. You can generally identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “guidance,” “outlook,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “foresee,” “potential” or “continue” or the negative of these terms or other similar expressions that concern our expectations, strategy, plans or intentions.

We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including but not limited to: the risk that our strategic partnership with Koddi may not yield the anticipated benefits, advertiser adoption, or scale across the US and European markets as expected; technical and operational challenges related to the OpenRTB integration; the highly competitive nature of the digital, CTV, and retail media advertising markets; and the other important risks described in the section entitled “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q filed for the quarters ended March 31, 2026, and June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”), which are available on our website at https://investors.teads.com/ and on the SEC’s website at www.sec.gov.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Media Contact 
press@teads.com

Vaisala Corporation 
Managers’ Transactions 
September 29, 2026, at 11:30 a.m. (EEST) 

Vaisala Corporation: Managers’ Transactions – Björklund, Elina
____________________________________________

Person subject to the notification requirement
Name: EBIT OY
Position: Closely associated person
(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer
Name: ELINA BJÖRKLUND
Position: Member of the Board

Issuer: VAISALA OYJ
LEI: 743700RNDD7KU11HW873

Notification type: INITIAL NOTIFICATION
Reference number: 173947/5/4

and:
Notification type: AMENDMENT
Reference number: 173947/6/4
Information regarding the Position has been updated.
____________________________________________

Transaction date: 2026-09-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009900682
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 600 Unit price: 60 EUR

Aggregated transactions (1):
Volume: 600 Volume weighted average price: 60 EUR

More information: 
Niina Ala-Luopa , investor relations
+358 400 728 957, ir@vaisala.com

Distribution: 
Nasdaq Helsinki 
Key media 
vaisala.com 

Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With over 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.
www.vaisala.com

Vaisala Corporation 
Managers’ Transactions 
September 29, 2026, at 11:30 a.m. (EEST) 

Vaisala Corporation: Managers’ Transactions – Björklund, Elina
____________________________________________

Person subject to the notification requirement
Name: EBIT OY
Position: Closely associated person
(X) Legal person

(1): Person Discharging Managerial Responsibilities In Issuer
Name: ELINA BJÖRKLUND
Position: Member of the Board

Issuer: VAISALA OYJ
LEI: 743700RNDD7KU11HW873

Notification type: INITIAL NOTIFICATION
Reference number: 173947/5/4

and:
Notification type: AMENDMENT
Reference number: 173947/6/4
Information regarding the Position has been updated.
____________________________________________

Transaction date: 2026-09-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009900682
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 600 Unit price: 60 EUR

Aggregated transactions (1):
Volume: 600 Volume weighted average price: 60 EUR

More information: 
Niina Ala-Luopa , investor relations
+358 400 728 957, ir@vaisala.com

Distribution: 
Nasdaq Helsinki 
Key media 
vaisala.com 

Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With over 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange.
www.vaisala.com

Auction	Auction results
Auction date	2026-09-29
Start date	2026-09-30
Maturity date	2026-10-07
Interest rate	1.75 %
Offered volume, SEK bn	471.0
Total bid amount, SEK bn	340.150
Accepted volume, SEK bn	340.150
Number of bids	14
Percentage allotted, %	100.00

Auction	Auction results
Auction date	2026-09-29
Start date	2026-09-30
Maturity date	2026-10-07
Interest rate	1.75 %
Offered volume, SEK bn	471.0
Total bid amount, SEK bn	340.150
Accepted volume, SEK bn	340.150
Number of bids	14
Percentage allotted, %	100.00

Marks a major milestone in Nasdaq Calypso’s strategy to serve as the trusted orchestration layer connecting agents across capital market and treasury workflows

Introduces agentic capabilities, including a natural language assistant to automate analysis of the platform’s system-of-record data

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today launched a framework for integrating AI capabilities within capital market and treasury operations, addressing some of the bottlenecks that are preventing scaled institutional adoption. At its core, Nasdaq has established an agentic AI operating environment within its Nasdaq Calypso platform, providing financial institutions with a contained, governed space to run, connect, and scale AI agents across the trade lifecycle.

“For institutions to adopt AI agents at scale, they need a trusted, governed infrastructure inside the capital market platforms they already run, a place to connect agents from many different sources to real workflows, data, and controls,” said Magnus Haglind, Head of Capital Markets Technology at Nasdaq. “By integrating agentic capabilities and serving as the orchestration layer, we are evolving Nasdaq Calypso from a system of record into an intelligent platform that automates activity at every stage of the trade lifecycle.”

AI has enormous potential across capital market workflows to enhance risk controls, reduce settlement failures, and transform operational data into automated actions. According to a recent Nasdaq and Acuiti survey, almost half of respondents highlighted challenges relating to manual intervention within their post-trade operations, while 56% said they risk losing ground to competitors if they do not integrate AI or machine learning into their clearing operations.

How the Nasdaq Calypso Agentic AI Environment Will Work

Nasdaq Calypso is an advanced capital markets and treasury platform used by banks, brokers, asset managers, central banks, and other financial institutions to process front-to-back office trading, risk management, and collateral workflows. The operating environment will allow clients to access Nasdaq Calypso’s agents and connect their own proprietary AI infrastructure through an integrated layer built on the Model Context Protocol (MCP). MCP is an emerging industry standard for linking AI agents to software.

The environment applies robust operational boundaries, live oversight, and strict sandboxing with no external data retention, designed to keep AI agents operating solely within an institution’s perimeter and policies. It will enable agents to operate on core Nasdaq Calypso data, drawing on the platform’s system-of-record trading, risk, and collateral records, and can be extended with additional enterprise, market, and reference data sources.

Today’s launch also aligns with the first agentic capabilities available in the environment: a natural language assistant that lets users query the platform’s data, documentation, and other information. The functionality seeks to deepen how teams can use the platform, enhance productivity around data analysis and document review, and accelerate decision-making.

Nasdaq plans to roll out a suite of governed agentic workers designed to address operational friction caused by manual processes that persist across capital market workflows.

Clients retain full control of their data. The agents will be hosted by Nasdaq and delivered through Nasdaq Calypso’s cloud environment, which is built on Amazon Bedrock to provide the scalable services and governance controls required to run agentic AI in regulated environments. On-premises clients will also be able to connect to those same agents.

Nasdaq will partner with individual clients as they work through internal AI governance and control requirements to bring these capabilities online. The launch builds on Nasdaq’s extensive AI capabilities within its suite of Financial Technology platforms, including Nasdaq Verafin’s Agentic AI workforce leveraged by 800+ clients, and AI-powered regulatory reporting in Nasdaq AxiomSL. As institutions increasingly adopt these technology platforms, the patterns learned are expected to help deliver even greater levels of performance and client outcomes.

Media contact:

Andrew Hughes; +44 (0)7443 100896; Andrew.Hughes@nasdaq.com  

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying the technology, data, and advanced analytics that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

-NDAQG-

© 2026 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon’ logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, “Nasdaq”), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.

Cautionary Note Regarding Forward-Looking Statements:  

Information set forth in this press release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as “will,” “can,” “enable,” “plans ” “seeks,” “designed to” and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to the performance and benefits of Nasdaq Calypso and its AI capabilities, including agentic functionality. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These risks and uncertainties are detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  

Marks a major milestone in Nasdaq Calypso’s strategy to serve as the trusted orchestration layer connecting agents across capital market and treasury workflows

Introduces agentic capabilities, including a natural language assistant to automate analysis of the platform’s system-of-record data

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today launched a framework for integrating AI capabilities within capital market and treasury operations, addressing some of the bottlenecks that are preventing scaled institutional adoption. At its core, Nasdaq has established an agentic AI operating environment within its Nasdaq Calypso platform, providing financial institutions with a contained, governed space to run, connect, and scale AI agents across the trade lifecycle.

“For institutions to adopt AI agents at scale, they need a trusted, governed infrastructure inside the capital market platforms they already run, a place to connect agents from many different sources to real workflows, data, and controls,” said Magnus Haglind, Head of Capital Markets Technology at Nasdaq. “By integrating agentic capabilities and serving as the orchestration layer, we are evolving Nasdaq Calypso from a system of record into an intelligent platform that automates activity at every stage of the trade lifecycle.”

AI has enormous potential across capital market workflows to enhance risk controls, reduce settlement failures, and transform operational data into automated actions. According to a recent Nasdaq and Acuiti survey, almost half of respondents highlighted challenges relating to manual intervention within their post-trade operations, while 56% said they risk losing ground to competitors if they do not integrate AI or machine learning into their clearing operations.

How the Nasdaq Calypso Agentic AI Environment Will Work

Nasdaq Calypso is an advanced capital markets and treasury platform used by banks, brokers, asset managers, central banks, and other financial institutions to process front-to-back office trading, risk management, and collateral workflows. The operating environment will allow clients to access Nasdaq Calypso’s agents and connect their own proprietary AI infrastructure through an integrated layer built on the Model Context Protocol (MCP). MCP is an emerging industry standard for linking AI agents to software.

The environment applies robust operational boundaries, live oversight, and strict sandboxing with no external data retention, designed to keep AI agents operating solely within an institution’s perimeter and policies. It will enable agents to operate on core Nasdaq Calypso data, drawing on the platform’s system-of-record trading, risk, and collateral records, and can be extended with additional enterprise, market, and reference data sources.

Today’s launch also aligns with the first agentic capabilities available in the environment: a natural language assistant that lets users query the platform’s data, documentation, and other information. The functionality seeks to deepen how teams can use the platform, enhance productivity around data analysis and document review, and accelerate decision-making.

Nasdaq plans to roll out a suite of governed agentic workers designed to address operational friction caused by manual processes that persist across capital market workflows.

Clients retain full control of their data. The agents will be hosted by Nasdaq and delivered through Nasdaq Calypso’s cloud environment, which is built on Amazon Bedrock to provide the scalable services and governance controls required to run agentic AI in regulated environments. On-premises clients will also be able to connect to those same agents.

Nasdaq will partner with individual clients as they work through internal AI governance and control requirements to bring these capabilities online. The launch builds on Nasdaq’s extensive AI capabilities within its suite of Financial Technology platforms, including Nasdaq Verafin’s Agentic AI workforce leveraged by 800+ clients, and AI-powered regulatory reporting in Nasdaq AxiomSL. As institutions increasingly adopt these technology platforms, the patterns learned are expected to help deliver even greater levels of performance and client outcomes.

Media contact:

Andrew Hughes; +44 (0)7443 100896; Andrew.Hughes@nasdaq.com  

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying the technology, data, and advanced analytics that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

-NDAQG-

© 2026 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon’ logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, “Nasdaq”), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.

Cautionary Note Regarding Forward-Looking Statements:  

Information set forth in this press release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as “will,” “can,” “enable,” “plans ” “seeks,” “designed to” and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to the performance and benefits of Nasdaq Calypso and its AI capabilities, including agentic functionality. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These risks and uncertainties are detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.